Search Results - "Javaid, Amal M"

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma by Goldberg, Jacob L, Navid, Fariba, Hank, Jacqueline A, Erbe, Amy K, Santana, Victor, Gan, Jacek, de Bie, Fenna, Javaid, Amal M, Hoefges, Anna, Merdler, Michael, Carmichael, Lakeesha, Kim, KyungMann, Bishop, Michael W, Meager, Michael M, Gillies, Steven D, Pandey, Janardan P, Sondel, Paul M

“…PurposePatients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against…”
Get full text

Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC by Swick, Adam D, Prabakaran, Prashanth J, Miller, Margot C, Javaid, Amal M, Fisher, Michael M, Sampene, Emmanuel, Ong, Irene M, Hu, Rong, Iida, Mari, Nickel, Kwangok P, Bruce, Justine Y, Wheeler, Deric L, Kimple, Randall J

“…Head and neck squamous cell carcinomas (HNSCC) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of…”
Get full text

Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition by Prabakaran, Prashanth J, Javaid, Amal M, Swick, Adam D, Werner, Lauryn R, Nickel, Kwangok P, Sampene, Emmanuel, Hu, Rong, Ong, Irene M, Bruce, Justine Y, Hartig, Gregory K, Wieland, Aaron M, Canon, Jude, Harari, Paul M, Kimple, Randall J

“…Adenoid cystic carcinoma (ACC) is a rare cancer arising from the major or minor salivary gland tissues of the head and neck. There are currently no approved…”
Get full text

Abstract 51: Potential and challenges in co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC by Swick, Adam D., Prabakaran, Prashanth J., Miller, Margot C., Javaid, Amal M., Fisher, Michael M., Sampene, Emmanuel, Ong, Irene M., Iida, Mari, Wheeler, Deric L., Nickel, Kwangok P., Bruce, Justine Y., Kimple, Randall J.

“…Background: Head and neck squamous cell carcinomas (HNSCCs) have high rates of mutation and other alterations along the PI3K/AKT/mTORC signaling axis. This has…”
Get full text

Co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC by Swick, Adam D, Prabakaran, Prashanth Jyothi, Miller, Margot, Javaid, Amal M, Fisher, Michael, Sampene, Emmanuel, Ong, Irene, Iida, Mari, Nickel, Kwang-Ok P, Bruce, Justine Yang, Wheeler, Deric, Kimple, Randall J.

“…Abstract only e17509 Background: Head and neck squamous cell carcinomas (HNSCCs) are frequently altered along the PI3K/AKT/mTORC signaling axis leading to…”
Get full text

Co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC by Swick, Adam D., Prabakaran, Prashanth J., Miller, Margot C., Javaid, Amal M., Fisher, Michael M., Sampene, Emmanuel, Ong, Irene M., Hu, Rong, Iida, Mari, Nickel, Kwangok P., Bruce, Justine Y., Wheeler, Deric L, Kimple, Randall J.

“…Head and neck squamous cell carcinomas (HNSCCs) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of…”
Get full text